"Amazon Pharmacy's decision to stock Foundayo at One Medical kiosks represents a significant shift in how Americans can access weight-loss medications, with plans for same-day home delivery."
"Eli Lilly's Zepbound generated $4.26 billion in revenue in Q4 2025, showcasing the growing demand for GLP-1 drugs and the financial impact of Amazon's partnership."
"CVS Health's involvement in GLP-1 distribution through its retail pharmacies and Caremark pharmacy benefit manager positions it strategically in the evolving market."
"Viking Therapeutics is developing VK2735, a dual GLP-1/GIP agonist, which could benefit from the increasing validation of the GLP-1 market and its potential growth."
Amazon Pharmacy announced it will stock the GLP-1 weight-loss pill Foundayo at One Medical kiosks, offering same-day home delivery. This expansion aims to reach 4,500 locations by the end of 2026. Eli Lilly, which produces Foundayo, benefits significantly as Amazon serves as a key dispensing partner. CVS Health and Novo Nordisk are also involved in GLP-1 distribution, with CVS managing formulary status and Novo's Wegovy already available at Amazon kiosks. Viking Therapeutics is developing a related drug, VK2735, enhancing its investment appeal.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]